fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Beyond the Headlines: FDA Warning

Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is essential to maintaining glycaemic safety which is one reason why retatrutide must only be used under close medical supervision

Unlike injectable obesity drugs, which are peptides designed to mimic the appetite-controlling GLP-1 hormone, orforglipron is a small molecule pill that is easier to manufacture and package, said Kenneth Custer, president of Lilly's cardiometabolic health division

They represent genuine cellular protection during a period of significant physical change

Im overweight but dont have diabetes